The development of intravenous busulfan (Bu) and its incorporation in the preparative
regimens for allogeneic stem cell transplantation has changed transplantation for …

PURPOSE Total body irradiation (TBI) before allogeneic hematopoietic stem cell
transplantation (HSCT) in pediatric patients with acute lymphoblastic leukemia (ALL) is …

Abstract The Practice Guidelines Committee of the American Society of Blood or Marrow
Transplantation (ASBMT) sought to develop an evidence-based review about personalizing …

Background Intravenous busulfan combined with therapeutic drug monitoring to guide
dosing improves outcomes after allogeneic haemopoietic cell transplantation (HCT). The …

We conducted a prospective cohort study testing the noninferiority of survival of ablative
intravenous busulfan (IV-BU) vs ablative total body irradiation (TBI)-based regimens in …

Fire is one of the main disturbances of tropical forests. Understanding the spatial and
temporal dynamics of forest fires is of fundamental importance for the conservation of …

We report the international experience in outcomes after related and unrelated
hematopoietic transplantation for infantile osteopetrosis in 193 patients. Thirty-four percent …

Busulfan (Bu) is used as a myeloablative agent in conditioning regimens before allogeneic
hematopoietic cell transplantation (allo-HCT). In line with strategies explored in adults …

We prospectively studied the pharmacokinetics (PK) and clinical outcomes of intravenous
busulfan (Bu) in 71 children with preexisting liver damage who underwent hematopoietic …

A retrospective population pharmacokinetic (PPK) analysis was performed in 24 pediatric
patients (PEDS)(0.45–16.7 years old) receiving iv busulfan/cyclophosphamide (iv Bu/Cy 4) …